Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
大量的历史交易数据，为您的融资、许可、合作与收购项目提供重要参考。
As a business and portfolio strategy professional, it’s important that you understand the diseases and market landscape, unmet needs, and the best candidates available for in-licensing, out-licensing or acquisition. To best evaluate your target list, you need to benchmark other relevant transactions in the space, and compare deal structures and mix of financial payments and milestones. You’ll want to:
Alerts for these potential opportunities are a must-have.
How we can help
With our comprehensive coverage of industry meetings and financial conferences, and analyst calls, we arm you with timely and accurate intelligence you can act on, including:
Real-time tracking and analysis of the drug development pipeline
Key benefits:
The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.
Key benefits:
Key benefits:
Scrip
By Ian Schofield 29 Nov 2022
Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.
Topic Cancer
Scrip
By Jessica Merrill 14 Nov 2022
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
Scrip
By Jessica Merrill 14 Nov 2022
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
Scrip
By Mandy Jackson 14 Nov 2022
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Scrip
By Jung Won Shin 25 Oct 2022
AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.
Topic Company Analysis Strategy
Scrip
20 Oct 2022
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
Biomedtracker, Meddevicetracker
23 May 2022
In this report, we cover catalysts from 31 drugs, devices, diagnostics, and deals expected to occur in the second quarter of 2022.
Topic Outlook
Chemist + Druggist Data
11 Mar 2022
We are pleased to announce that from mid-February 2022, C+D Data will provide the UK supply chain with additional product listings and associated PIP-codes for Northern Ireland (NI) and Great Britain (GB.) This solution will allow you to reach the entire UK market quickly and facilitate the ordering and distribution of medicines without disruption to you, and your wholesalers – while ensuring the data’s accuracy, visibility, and long-term management.
Biomedtracker, Meddevicetracker
08 Feb 2022
In pharma’s fast paced and continually evolving world, accurately anticipating the impact of events on the horizon is critical to your success.
Topic Business Strategies
Scrip
By Scrip Team 18 Jan 2022
More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine.
Scrip
By Joseph Haas 17 Jan 2022
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Scrip
By Ian Haydock 17 Jan 2022
In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.
Scrip
By Scrip Team 17 Jan 2022
Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.
HBW Insight
By Ryan Nelson 14 Jan 2022
Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.
Scrip
By Alaric DeArment 10 Jan 2022
At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.
HBW Insight
02 Jun 2023
Scrip
02 Jun 2023
Scrip
02 Jun 2023
HBW Insight
02 Jun 2023
HBW Insight
02 Jun 2023
Scrip
02 Jun 2023
Scrip
02 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
HBW Insight
01 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
报告商城
迫切需要某一领域的的全面信息？
不妨在我们的报告商城中搜索是否有符合您需求的相关报告—— 海量实用报告供您甄选。
